Kinase inhibitors

1. A compound of the general formula:

or pharmaceutically acceptable salts, or diastereomers thereof, wherein:

D is:

R 2 is 0-4 substituents independently chosen from H, halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , OCF 3 , aryl, hetaryl, C 1-4 alkylOC 1-4 alkyl, C 1-4 alkylOaryl, C 1-4 alkylNR 3 R 4 , CO 2 R 3 , CONR 3 R 4 , CONR 3 SO 2 R 4 , NR 3 R 4 , C 1-4 alkylNR 3 R 4 , nitro, NR 3 COR 4 , NR 5 CONR 3 R 4 , NR 3 SO 2 R 4 , C 1-4 alkylNR 3 COR 4 , C 1-4 alkylNR 5 CONR 3 R 4 , or C 1-4 alkylNR 3 SO 2 R 4 ;

R 3 and R 4 are each independently H, halogen, CH 2 F, CHF 2 , CF 3 , C 1-4 alkyl, C 1-4 alkyl cycloalkyl, C 1-4 cyclohetalkyl, aryl, C 1-4 alkyl aryl, hetaryl, C 1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered (saturated or unsaturated) ring optionally containing an atom selected from O, S, NR 6 ;

R 5 is H, C 1-4 alkyl, halogen, CH 2 F, CHF 2 , CF 3 , aryl or hetaryl;

R 6 is H, C 1-4 alkyl, aryl, hetaryl, C 1-4 alkyl aryl, or C 1-4 alkyl hetaryl;

R 1 is H, C 1-4 alkyl, C 1-6 cycloalkyl;

Q is a bond, CH 2 , C 1-4 alkyl;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , OCF 3 , CN, NR 8 R 9 , aryl, hetaryl, C 1-4 aryl, C 1-4 hetaryl, C 1-4 alkylNR 8 R 9 , OC 1-4 alkylNR 8 R 9 , nitro, NR 10 C 1-4 NR 8 R 9 , NR 8 COR 9 , NR 10 CONR 8 R 9 , NR 8 SO 2 R 9 , CONR 8 R 9 , or CO 2 R 8 , where R 8 and R 9 are each independently H, C 1-4 alkyl, aryl or which together form an optionally substituted 4-8 membered ring which may contain a heteroatom selected from O, S, NR 11 , where R 11 is C 1-4 alkyl, and R 10 is selected from H, C 1-4 alkyl; and

where Q is CH 2 or C 1-4 alkyl, W is H, C 1-4 alkyl, or C 2-6 alkenyl, where C 1-4 alkyl or C 2-6 alkenyl may be optionally substituted with C 1-4 alkyl, OH, OC 1-4 alkyl, NR 12 R 13 ; and R 12 , and R 13 are each independently H, C 1-4 alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, and NR 14 where R 14 is H or C 1-4 alkyl.

2. The compound of claim 1 of the general formula II

or pharmaceutically acceptable salts, or diastereomers thereof, wherein:

D is:

R 2 is 0-4 substituents independently chosen from H, halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , OCF 3 , aryl, hetaryl, C 1-4 alkylOC 1-4 alkyl, C 1-4 alkylOaryl, C 1-4 alkylNR 3 R 4 , CO 2 R 3 , CONR 3 R 4 , CONR 3 SO 2 R 4 , nitro, NR 3 R 4 , C 1-4 alkylNR 3 R 4 , NR 3 COR 4 , NR 5 CONR 3 R 4 , NR 3 SO 2 R 4 , C 1-4 alkylNR 3 COR 4 , C 1-4 alkylNR 5 CONR 3 R 4 , or C 1-4 alkylNR 3 SO 2 R 4 ;

R 3 and R 4 are each independently H, halogen, CH 2 F, CHF 2 , CF 3 , C 1-4 alkyl, C 1-4 alkyl cycloalkyl, C 1-4 cyclohetalkyl, aryl, C 1-4 alkyl aryl, hetaryl, C 1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered (saturated or unsaturated) ring optionally containing an atom selected from O, S, NR 6 ;

R 5 is H, C 1-4 alkyl, halogen, CH 2 F, CHF 2 , CF 3 , aryl or hetaryl;

R 6 is H, C 1-4 alkyl, aryl, hetaryl, C 1-4 alkyl aryl, or C 1-4 alkyl hetaryl;

R 1 is H, C 1-4 alkyl, or C 1-6 cycloalkyl;

W is H or C 1-4 alkyl; and

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , OCF 3 , CN, nitro, NR 8 R 9 , aryl, hetaryl, C 1-4 aryl, C 1-4 hetaryl, C 1-4 alkylNR 8 R 9 , OC 1-4 alkylNR 8 R 9 , NR 10 C 1-4 NR 8 R 9 , NR 8 COR 9 , NR 10 CONR 8 R 9 , NR 8 SO 2 R 9 , CONR 8 R 9 , or CO 2 R 8 , where R 8 and R 9 are each independently H, C 1-4 alkyl, aryl or which together form an optionally substituted 4-8 membered ring which may contain a heteroatom selected from O, S, and NR 11 , where R 11 is C 1-4 alkyl, and R 10 is H or C 1-4 alkyl.

3. The compound of claim 1 , where W is C 1-4 alkyl wherein the compound possesses S chirality at the chiral carbon bearing W.

4. The compound of claim 3 , wherein the compound is a mixture of R and S isomers and the mixture comprises at least 70% of the S isomer.

5. The compound of claim 4 , wherein the compound comprises at least 80% of the S isomer.

6. The compound of claim 5 , wherein the compound comprises at least 90% of the S isomer.

7. The compound of claim 6 , wherein the compound comprises at least 95% of the S isomer.

8. The compound of claim 7 , wherein the compound comprises at least 99% of the S isomer.

9. A composition comprising a carrier and at least one compound of claim 1 .